This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general adiposity, shows a new analysis of the SUMMIT trial.
Medscape Medical News